Efficacy News and Research

RSS

Mortality, morbidity rates linked with AF remain 'unacceptably high' despite new treatments

Despite recent advances in the treatment of heart rhythm disturbances, mortality and morbidity rates associated with atrial fibrillation (AF) remain "unacceptably high", according to a new report.

27 Jun 2011

New model estimates impact of lifestyle changes on absolute breast cancer risk

How much can a woman lower her risk of breast cancer by losing weight, drinking less, or exercising more? A study published online June 24 in the Journal of the National Cancer Institute describes a new model to estimate the impact of these lifestyle changes on absolute breast cancer risk, suggesting risk reductions that could translate into a substantial number of prevented cancers across an entire population.

27 Jun 2011

Intravenous diclofenac holds promise against severe pain following oral surgery

An essential aspect of oral surgery is controlling the patient's pain following a procedure. The goal is to relieve pain and promote a rapid recovery, without opioid side effects. An initial study shows that Dyloject, a new intravenous form of the drug diclofenac, has promise for achieving these goals.

27 Jun 2011

Diabetic patients can benefit from basal insulin analogs

Basal insulin analogs have revolutionized diabetes care, and especially the treatment of type 2 diabetes, enabling patients to achieve better control of blood glucose levels while reducing hypoglycemic episodes.

27 Jun 2011

Short-term lowering of PreDx DRS may reduce risk of developing diabetes

Data presented today from an analysis of samples from the European Diabetes Prevention Study (EDIPS) showed that the PreDx Diabetes Risk Score (DRS) is lowered by lifestyle intervention, which correlates to a reduction in the risk that patients will develop diabetes over time.

27 Jun 2011

New data from Zafgen's ZGN-433 Phase 1b study on obesity presented at ADA 2011

Zafgen, Inc., a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced new data from a Phase 1b study of ZGN-433, a selective methionine aminopeptidase 2 inhibitor (MetAP2), which showed a significant improvement in cardiovascular risk markers in severely obese subjects.

27 Jun 2011

EMA CHMP recommends approval of linagliptin for type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today received a positive opinion from the European Medicines Agency's (EMA) medicinal committee recommending approval of linagliptin, 5 mg, film-coated tablets (to be marketed under the trade name Trajenta® in Europe) for the treatment of adults with type 2 diabetes.

24 Jun 2011

Scientific evidence is key driver for gaining reimbursement for MR-guided focused ultrasound

Medical researchers have a critical role to play in gaining optimal health insurance reimbursement for MR-guided focused ultrasound. As Susan Klees, Director of Patient Access for the Focused Ultrasound Surgery Foundation, reports, "Scientific evidence is the key driver for reimbursement, and it all begins with the way studies are designed. Today, research priorities must be grounded in sound science as well as the realities of the marketplace."

24 Jun 2011

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

Baxter International Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy (MMN), a severe, debilitating disorder requiring lifelong treatment.

From Baxter International Inc. 24 Jun 2011

PCIB reports main results of Amphinex Phase I/II study against multiple cancers

PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today the main results of the completed Phase I/II study of the new component Amphinex in the combination productPC-A11, where Amphinex is used in combination with the cytotoxic agent bleomycin.

24 Jun 2011

Scientists analyse factors that influence development of burnout syndrome

Being over-burdened with work, monotony and the perception of lack of recognition can all be catalysts for burnout syndrome. A team of scientists has analysed the factors that influence the development of the three sub-types of this condition - 'frenetic', 'under-challenged' and 'worn out'.

24 Jun 2011

Lithium can prevent aggregation of toxic proteins and cell loss linked with Parkinson's

Lithium profoundly prevents the aggregation of toxic proteins and cell loss associated with Parkinson's disease (PD) in a mouse model of the condition.

24 Jun 2011

Electrophysiology mapping and ablation devices market to reach over $2.1B by 2017

By 2017, the global electrophysiology mapping and ablation devices market is likely to achieve a value of $2.1 billion, according to a new report on companiesandmarkets.com. An ageing population, an increased number of diagnoses and several clinical studies have encouraged market growth.

24 Jun 2011

Adeona enters agreement to begin proprietary zinc-based therapy Phase IIb trial in ALS

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has expanded its pipeline of proprietary zinc-based therapies to include a planned Phase IIb clinical trial of patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease.

24 Jun 2011

Arno AR-67 Phase II clinical study for glioblastoma meets pre-defined interim goals

Arno Therapeutics, Inc. announced today that its Phase II clinical study of AR-67 has met pre-defined interim goals for patients with glioblastoma multiforme (GBM) who were not previously treated with Avastin and will continue toward completion.

23 Jun 2011

Health Canada approves PURE Hard Surface disinfectant

PURE Bioscience, Inc., creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that Health Canada has approved PURE™ Hard Surface disinfectant for use in food premises, hospitals and health care facilities, domestic locations and institutional and industrial premises.

23 Jun 2011

Proton beam radiotherapy appears to control breast cancer with minimal side-effects

A treatment that has virtually no side effects has been found to be an effective weapon for fighting early-stage breast cancer, according to results of a clinical trial conducted at Loma Linda University Medical Center.

23 Jun 2011

St. Jude Medical announces results of Genesis neurostimulator trial on chronic migraine

St. Jude Medical, Inc., a global medical device company, today announced study results on the safety and efficacy of peripheral nerve stimulation (PNS) of the occipital nerve for the management of pain and disability associated with chronic migraine, a debilitating condition that affects millions worldwide.

23 Jun 2011

Diamyd Medical to terminate US DiaPrevent Phase III study for type 1 diabetes

Diamyd Medical AB reports that the Company has decided to suspend dosing in a US Phase III study with the antigen-based therapy Diamyd and to initiate closure of the study.

23 Jun 2011

ULMCA PCI with DES a viable option for low-risk patients with normal left ventricular function

Patients with normal left ventricular function who undergo elective unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with drug-eluting stents (DES) had favorable outcomes according to new research.

23 Jun 2011

Efficacy News and Research

Mortality, morbidity rates linked with AF remain 'unacceptably high' despite new treatments

New model estimates impact of lifestyle changes on absolute breast cancer risk

Intravenous diclofenac holds promise against severe pain following oral surgery

Diabetic patients can benefit from basal insulin analogs

Short-term lowering of PreDx DRS may reduce risk of developing diabetes

New data from Zafgen's ZGN-433 Phase 1b study on obesity presented at ADA 2011

EMA CHMP recommends approval of linagliptin for type 2 diabetes

Scientific evidence is key driver for gaining reimbursement for MR-guided focused ultrasound

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

PCIB reports main results of Amphinex Phase I/II study against multiple cancers

Scientists analyse factors that influence development of burnout syndrome

Lithium can prevent aggregation of toxic proteins and cell loss linked with Parkinson's

Electrophysiology mapping and ablation devices market to reach over $2.1B by 2017

Adeona enters agreement to begin proprietary zinc-based therapy Phase IIb trial in ALS

Arno AR-67 Phase II clinical study for glioblastoma meets pre-defined interim goals

Health Canada approves PURE Hard Surface disinfectant

Proton beam radiotherapy appears to control breast cancer with minimal side-effects

St. Jude Medical announces results of Genesis neurostimulator trial on chronic migraine

Diamyd Medical to terminate US DiaPrevent Phase III study for type 1 diabetes

ULMCA PCI with DES a viable option for low-risk patients with normal left ventricular function

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News